Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C18H29NO3 |
| Molecular Weight | 307.4278 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CC(C)(C)COC(=O)C(CO)C1=CC=CC=C1
InChI
InChIKey=ORXLOAFNULMXBG-UHFFFAOYSA-N
InChI=1S/C18H29NO3/c1-5-19(6-2)13-18(3,4)14-22-17(21)16(12-20)15-10-8-7-9-11-15/h7-11,16,20H,5-6,12-14H2,1-4H3
| Molecular Formula | C18H29NO3 |
| Molecular Weight | 307.4278 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
AMPROTROPINE (Syntropan) is the phosphate salt of
3 diethylamine, 2.2 dimethylpropanol
tropic acid ester. Syntropan is antispasmodic. Its main effect is parasympathetic, and its internal uses are
chiefly the same as those of atropine. Syntropan produces relaxation of the tone of the stomach and inhibition of peristaltic activity. The effect of syntropan on gastric secretion excited by a meat extract meal and histamine is weak as compared with atropine. Its
advantages as a mydriatic were also described: the rapid effect; the short duration; no general dangers nor discomforts; no local dangers, as damaging the corneal epithelium, or increasing the intraocular
pressure; no delay in returning to work for the patient.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18123466
Intravenous administration of Syntropan, in doses of 10–25 mg, decreased tonus and abolished waves for short periods of time in the stomach, duodenum, jejunum, ileum and colon, and also retarded transport of the balloon through the stomach and intestine. Undesirable side effects were encountered in all patients given the drug intravenously in doses of 10–25 mg.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:23:12 GMT 2025
by
admin
on
Mon Mar 31 18:23:12 GMT 2025
|
| Record UNII |
Q1S268DPRS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Mon Mar 31 18:23:12 GMT 2025 , Edited by admin on Mon Mar 31 18:23:12 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C053014
Created by
admin on Mon Mar 31 18:23:12 GMT 2025 , Edited by admin on Mon Mar 31 18:23:12 GMT 2025
|
PRIMARY | |||
|
148-32-3
Created by
admin on Mon Mar 31 18:23:12 GMT 2025 , Edited by admin on Mon Mar 31 18:23:12 GMT 2025
|
PRIMARY | |||
|
8645
Created by
admin on Mon Mar 31 18:23:12 GMT 2025 , Edited by admin on Mon Mar 31 18:23:12 GMT 2025
|
PRIMARY | |||
|
DTXSID90933277
Created by
admin on Mon Mar 31 18:23:12 GMT 2025 , Edited by admin on Mon Mar 31 18:23:12 GMT 2025
|
PRIMARY | |||
|
C79938
Created by
admin on Mon Mar 31 18:23:12 GMT 2025 , Edited by admin on Mon Mar 31 18:23:12 GMT 2025
|
PRIMARY | |||
|
Q1S268DPRS
Created by
admin on Mon Mar 31 18:23:12 GMT 2025 , Edited by admin on Mon Mar 31 18:23:12 GMT 2025
|
PRIMARY | |||
|
3675
Created by
admin on Mon Mar 31 18:23:12 GMT 2025 , Edited by admin on Mon Mar 31 18:23:12 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |